This announcement is made in replacement of the 'Exercise of Options, Director Dealings and Total Voting Rights' announcement released on 23 August 2024 (RNS Number 4998B).
In the original announcement, Jerry Randall's beneficial interest in the Company both before and after the exercise of options was incorrect and has been corrected below.
All other details remain unchanged.
2 September 2024
VENTURE LIFE GROUP PLC
("Venture Life", "VLG" or the "Group")
Exercise of Options, Director Dealings and Total Voting Rights
Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that, on 21 August 2024, it has issued 404,599 new ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") following an exercise of options pursuant to the Company's Long-Term Incentive Plan ("LTIP") by Jerry Randall (Chief Executive Officer) and Gianluca Braguti (Chief Manufacturing officer) (together the "Exercising Directors").
Following the option exercise described above, the Exercising Directors' beneficial interests in the Company are set out below:
| Exercising Director | Current shareholding | Options exercised | Resultant shareholding |
| Jerry Randall | 2,084,865 | 224,274 | 2,309,139 |
| Gianluca Braguti | 3,742,730 | 180,325 | 3,923,055 |
Application has been made to the London Stock Exchange for the 404,599 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 29 August 2024.
Following Admission, the total number of Ordinary Shares in issue will be 127,052,312 and the total number of voting rights will therefore be 127,052,312. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
Cavendish Capital Markets Limited (Nomad and Broker) +44 (0) 20 7720 0500
Stephen Keys / Camilla Hume (Corporate Finance)
Michael Johnson (Sales)
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, Earol for ear wax removal, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.
Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.
The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| |
| a)
| Name
| Jerry Randall
|
| 2
| Reason for the notification
| |
| a)
| Position/status
| Chief Executive Officer |
| b)
| Initial notification /Amendment
| Initial notification |
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |
| a)
| Name
| Venture Life Group plc |
| b)
| LEI
| 213800S8CZUPLAB2KC70 |
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |
| a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares of 0.3p each in Venture Life Group plc
GB00BFPM8908 |
| b)
| Nature of the transaction
| Exercise of share options |
| c)
| Price(s) and volume(s)
| 224,274 Ordinary Shares at 0.3 pence per Ordinary Share
|
| d)
| Aggregated information
- Aggregated volume
- Price
| n/a
|
| e)
| Date of the transaction
| 21 August 2024 |
| f)
| Place of the transaction
| London Stock Exchange
|
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| |
| a)
| Name
| Gianluca Braguti
|
| 2
| Reason for the notification
| |
| a)
| Position/status
| Chief Manufacturing Officer |
| b)
| Initial notification /Amendment
| Initial notification |
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |
| a)
| Name
| Venture Life Group plc |
| b)
| LEI
| 213800S8CZUPLAB2KC70 |
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |
| a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares of 0.3p each in Venture Life Group plc
GB00BFPM8908 |
| b)
| Nature of the transaction
| Exercise of share options |
| c)
| Price(s) and volume(s)
| 180,325 Ordinary Shares at 0.3 pence per Ordinary Share
|
| d)
| Aggregated information
- Aggregated volume
- Price
| n/a
|
| e)
| Date of the transaction
| 21 August 2024 |
| f)
| Place of the transaction
| London Stock Exchange
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.